TrialA Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
Trial details
- Registry ID
- NCT07012395
- Phase
- Phase 2
SYRE
Spyre Therapeutics, Inc.
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
3Trials in this database
3Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative ColitisNCT07012395 | SYRE | Phase 2 | Recruiting | 2027-06Estimated |
| A Study of SPY072 in Rheumatic DiseaseNCT07148414 | SYRE | Phase 2 | Active not recruiting | 2026-10-31Estimated |
| Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBDNCT07652294 | SYRE | Phase 2 | Enrolling by invitation | 2029-03-02Estimated |
A Study of SPY072 in Rheumatic Disease
Trial details
- Registry ID
- NCT07148414
- Phase
- Phase 2
Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD
Trial details
- Registry ID
- NCT07652294
- Phase
- Phase 2
Latest recorded trial changes
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
NCT07012395 · Spyre Therapeutics, Inc.
Primary completion date changed
− Before
Jun 2026
+ After
Jun 2027
Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD
NCT07652294 · Spyre Therapeutics, Inc.
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: To assess the safety and tolerability of study drug treatment regimens
+ After
Measure: Percentage of participants who experienced an adverse event
A Study of SPY072 in Rheumatic Disease
NCT07148414 · Spyre Therapeutics, Inc.
Recruitment status changed
− Before
Recruiting
+ After
Active not recruiting